Ameliorating Contrast Induced Nephropathy After Coronary Angiography
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT06139952
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT06139952
-
- Other papers using this trial's data
- Preventing Contrast-Induced Acute Kidney Injury in Egyptian Patients Undergoing Coronary Angiography: A Randomized Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT06139952. Randomized; single masking; primary purpose prevention. Start 2023-12-01 (actual); primary completion 2024-03-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ameliorating Contrast Induced Nephropathy After Coronary Angiography
- Condition
- Coronary Artery Disease
- Condition
- Nephropathy; Toxic, Drugs
- Intervention (Drug)
- Atorvastatin 80mg
- Intervention (Drug)
- N-acetyl cysteine
- Intervention (Other)
- Normal Saline
- Lead sponsor
- Ain Shams University
Record details
- Record id
cardio:ct-nct06139952- Content hash
a7f7ffc4abc042623388e192b03f9c10ed3f9b0caedbf1b1254e4bbe7543f0b0